301015 百洋医药
已收盘 09-11 15:00:00
资讯
新帖
简况
百洋医药新提交“杰养氏”商标注册申请
证券之星 · 09-12 07:27
百洋医药新提交“杰养氏”商标注册申请
研报掘金丨华源证券：维持百洋医药“买入”评级，长期成长天花板有望打开
格隆汇 · 09-10
研报掘金丨华源证券：维持百洋医药“买入”评级，长期成长天花板有望打开
研报掘金丨华鑫证券：首予百洋医药“买入”评级，布局创新药械打造第二增长曲线
格隆汇 · 09-10
研报掘金丨华鑫证券：首予百洋医药“买入”评级，布局创新药械打造第二增长曲线
股市必读：百洋医药（301015）9月9日董秘有最新回复
证券之星 · 09-10
股市必读：百洋医药（301015）9月9日董秘有最新回复
百洋医药：H股发行上市工作正在有序推进
证券之星 · 09-07
百洋医药：H股发行上市工作正在有序推进
百洋医药：公司合作运营品牌的选择与更迭
证券之星 · 09-07
百洋医药：公司合作运营品牌的选择与更迭
百洋医药的“关键一跃”
蓝鲸财经 · 09-04
百洋医药的“关键一跃”
百洋医药（301015）披露累计诉讼、仲裁情况公告，9月2日股价下跌0.46%
证券之星 · 09-02
百洋医药（301015）披露累计诉讼、仲裁情况公告，9月2日股价下跌0.46%
百洋医药（301015）披露子公司为子公司提供担保的进展公告，9月1日股价下跌1.63%
证券之星 · 09-01
百洋医药（301015）披露子公司为子公司提供担保的进展公告，9月1日股价下跌1.63%
百洋医药：公司及控股子公司无逾期担保情况
证券日报 · 09-01
百洋医药：公司及控股子公司无逾期担保情况
百洋医药（301015）披露“质量回报双提升”行动方案进展，8月31日股价下跌2.35%
证券之星 · 08-31
百洋医药（301015）披露“质量回报双提升”行动方案进展，8月31日股价下跌2.35%
百洋医药（301015）2026年中报简析：净利润同比增长37.72%，盈利能力上升
证券之星 · 08-30
百洋医药（301015）2026年中报简析：净利润同比增长37.72%，盈利能力上升
百洋医药(301015)6月30日股东户数1.51万户，较上期增加0.69%
证券之星 · 08-29
百洋医药(301015)6月30日股东户数1.51万户，较上期增加0.69%
百洋医药最新公告：2026年半年度净利润同比增长37.72%
证券之星 · 08-28
百洋医药最新公告：2026年半年度净利润同比增长37.72%
百洋医药最新公告：拟4000万元投资济坤医药拓展器官纤维化领域布局
证券之星 · 08-28
百洋医药最新公告：拟4000万元投资济坤医药拓展器官纤维化领域布局
百洋医药（301015）披露归还临时补充流动资金的闲置募集资金公告，8月10日股价上涨1.51%
证券之星 · 08-10
百洋医药（301015）披露归还临时补充流动资金的闲置募集资金公告，8月10日股价上涨1.51%
百洋医药新提交“迪巧小粉条”商标注册申请
证券之星 · 08-08
百洋医药新提交“迪巧小粉条”商标注册申请
7月17日百洋医药跌6.32%，益民创新优势混合A基金重仓该股
证券之星 · 07-17
7月17日百洋医药跌6.32%，益民创新优势混合A基金重仓该股
百洋医药：提供ZAP-X放疗设备及配套技术支持
证券之星 · 07-17
百洋医药：提供ZAP-X放疗设备及配套技术支持
百洋医药（301015）披露为子公司提供担保的进展公告，7月9日股价上涨2.94%
证券之星 · 07-09
百洋医药（301015）披露为子公司提供担保的进展公告，7月9日股价上涨2.94%
暂无数据
公司概况
公司名称：
青岛百洋医药股份有限公司
所属行业：
批发业
上市日期：
2021-06-30
主营业务：
青岛百洋医药股份有限公司的主营业务是医学创新成果的产品开发、生产制造和商业化运营。公司的主要产品是品牌运营业务、批发配送业务。
发行价格：
7.64
{"stockData":{"symbol":"301015","market":"SZ","secType":"STK","nameCN":"百洋医药","latestPrice":23.39,"timestamp":1789110234000,"preClose":24.13,"halted":0,"volume":4183400,"delay":0,"changeRate":-0.0307,"floatShares":526000000,"shares":526000000,"eps":1.0202,"marketStatus":"已收盘","change":-0.74,"latestTime":"09-11 15:00:00","open":23.89,"high":24.17,"low":23.14,"amount":98173400,"amplitude":0.0427,"askPrice":23.43,"askSize":214,"bidPrice":23.39,"bidSize":111,"shortable":0,"etf":0,"ttmEps":1.0202,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":24.13,"symbolType":"stock","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":26.54,"lowLimit":21.72,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":525624077,"isCdr":false,"pbRate":5.53,"roa":"--","peRate":22.926877,"roe":"9.26%","epsLYR":0.9,"committee":0.073171,"marketValue":12294000000,"turnoverRate":0.008,"status":1,"floatMarketCap":12293000000},"requestUrl":"/m/hq/s/301015/tweets","defaultTab":"tweets","newsList":[{"id":"2666577905","title":"百洋医药新提交“杰养氏”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666577905?lang=zh_cn&edition=full","pubTime":"2026-09-12 07:27","pubTimestamp":1789169245,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日青岛百洋医药股份有限公司新提交“杰养氏”商标注册申请。商标申请详情如下：今年以来青岛百洋医药股份有限公司新申请注册商标7件，截止目前公司共持有注册商标437件，另有174件商标尚在注册申请中。通过天眼查大数据分析，青岛百洋医药股份有限公司共对外投资了37家企业，参与招投标项目326次；财产线索方面有商标信息570条，专利信息74条，著作权信息137条；此外企业还拥有行政许可64个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091200006596.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666569201","title":"研报掘金丨华源证券：维持百洋医药“买入”评级，长期成长天花板有望打开","url":"https://stock-news.laohu8.com/highlight/detail?id=2666569201","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666569201?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:12","pubTimestamp":1789031532,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["161027","BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666550251","title":"研报掘金丨华鑫证券：首予百洋医药“买入”评级，布局创新药械打造第二增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2666550251","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666550251?lang=zh_cn&edition=full","pubTime":"2026-09-10 14:23","pubTimestamp":1789021385,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["399265","161027","301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534736","title":"股市必读：百洋医药（301015）9月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666534736?lang=zh_cn&edition=full","pubTime":"2026-09-10 01:16","pubTimestamp":1788974171,"startTime":"0","endTime":"0","summary":"截至2026年9月9日收盘，百洋医药报收于24.6元，下跌1.68%，换手率0.93%，成交量4.89万手，成交额1.21亿元。董秘最新回复投资者： 9月份和扬州一洋的委托合同纠纷，属于扬州一洋欠贵司的推广服务费用，还是预付扬州一洋的货款支出？投资者： 董秘您好，截至7月31日的官方数据显示，吉伦泰已经顺利通过了2026年国家医保目录调整的初步形式审查。当日关注点交易信息汇总：9月9日主力资金净流出249.25万元，占总成交额2.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000001897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665316640","title":"百洋医药：H股发行上市工作正在有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2665316640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665316640?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:30","pubTimestamp":1788769831,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问H股上市进度怎样了？是否已经向港交所递交 上市申请？是否向中国证监会提交境外发行备案材料？百洋医药回复：尊敬的投资者您好，公司H股发行上市工作正在有序推进，重大进展会严格按照监管要求履行披露义务，请关注公司公告，感谢您的关注与支持。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700020892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665154353","title":"百洋医药：公司合作运营品牌的选择与更迭","url":"https://stock-news.laohu8.com/highlight/detail?id=2665154353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665154353?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:21","pubTimestamp":1788769274,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药09月07日在投资者关系平台上答复投资者关心的问题。同时公司年度报告中已没有海露，泌特，安斯泰来的哈乐、卫喜康、贝坦利系列，美罗华等产品的信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700019910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800253","title":"百洋医药的“关键一跃”","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800253","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664800253?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:42","pubTimestamp":1788482561,"startTime":"0","endTime":"0","summary":"文｜锦缎8月29日，百洋医药交出了一份乍看之下有些\"拧巴\"的半年报：2026上半年营业收入35.60亿元，同比下降5.11%；归母净利润2.25亿元，同比增长37.72%；扣非净利润2.21亿元，同比增长24.58%。01 迪巧的十年：利润底盘的自我巩固理解百洋医药，要先理解它的生意本质。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788234487093669382","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664681052","title":"百洋医药（301015）披露累计诉讼、仲裁情况公告，9月2日股价下跌0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664681052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664681052?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:47","pubTimestamp":1788360432,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，百洋医药报收于24.05元，较前一交易日下跌0.46%，最新总市值为126.41亿元。公司于近日披露《关于累计诉讼、仲裁情况的公告》。公告显示，青岛百洋医药股份有限公司及控股子公司连续十二个月内累计发生非重大诉讼、仲裁事项合计金额25,044.26万元，占公司最近一期经审计净资产的10.17%。公司不存在单个涉案金额达净资产10%以上且超1,000万元的重大诉讼、仲裁事项。除已披露案件外，无其他应披露未披露的诉讼、仲裁事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857343","title":"百洋医药（301015）披露子公司为子公司提供担保的进展公告，9月1日股价下跌1.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664857343?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:36","pubTimestamp":1788273378,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，百洋医药报收于24.16元，较前一交易日下跌1.63%，最新总市值为126.99亿元。近日，百洋医药披露《关于子公司为子公司提供担保的进展公告》。截至公告日，百洋制药对上海制药累计担保余额为7,119.70万元，上海制药可用担保额度为27,000万元。公司及控股子公司无逾期担保，未对合并报表外单位提供担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664768854","title":"百洋医药：公司及控股子公司无逾期担保情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2664768854","media":"证券日报 ","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664768854?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:26","pubTimestamp":1788269160,"startTime":"0","endTime":"0","summary":"9月1日，百洋医药发布公告称，本次提供担保后，公司及控股子公司的担保额度总金额为188，786.25万元，占公司最近一期经审计净资产的76.64%。截至本公告日，公司及控股子公司对外提供担保总余额为34，906.91万元，占公司最近一期经审计净资产的14.17%。公司及公司控股子公司不存在对合并报表外单位提供担保的情况。公司及控股子公司无逾期担保情况，无涉及诉讼的担保事项，不存在因担保被判决败诉而应承担损失的情形。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-01/doc-iniqitru3508308.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-01/doc-iniqitru3508308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663707158","title":"百洋医药（301015）披露“质量回报双提升”行动方案进展，8月31日股价下跌2.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663707158","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663707158?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:51","pubTimestamp":1788169897,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，百洋医药报收于24.56元，较前一交易日下跌2.35%，最新总市值为129.09亿元。该股当日开盘25.0元，最高25.05元，最低23.67元，成交额达2.11亿元，换手率为1.66%。近日，百洋医药披露《关于“质量回报双提升”行动方案的进展公告》。公告显示，公司持续推进“质量回报双提升”行动方案，聚焦医药主业，巩固品牌运营业务，迪巧、纽特舒玛等品牌保持市场领先地位，2026年上半年实现营业收入35.60亿元，归母净利润2.25亿元，同比增长37.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100025328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663404870","title":"百洋医药（301015）2026年中报简析：净利润同比增长37.72%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663404870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663404870?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:32","pubTimestamp":1788042751,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百洋医药发布2026年中报。截至本报告期末，公司营业总收入35.6亿元，同比下降5.11%，归母净利润2.25亿元，同比上升37.72%。按单季度数据看，第二季度营业总收入17.76亿元，同比下降7.05%，第二季度归母净利润1.01亿元，同比上升28.93%。本报告期百洋医药盈利能力上升，毛利率同比增幅9.24%，净利率同比增幅39.56%。去年的净利率为7.62%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000003258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012175","title":"百洋医药(301015)6月30日股东户数1.51万户，较上期增加0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012175","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012175?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:19","pubTimestamp":1787995188,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百洋医药披露，截至2026年6月30日公司股东户数为1.51万户，较3月31日增加103.0户，增幅为0.69%。在医药商业行业个股中，百洋医药股东户数低于行业平均水平，截至6月30日，医药商业行业平均股东户数为4.34万户。从股价来看，2026年3月31日至2026年6月30日，百洋医药区间跌幅为18.78%，在此期间股东户数增加103.0户，增幅为0.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662936440","title":"百洋医药最新公告：2026年半年度净利润同比增长37.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662936440","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662936440?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:40","pubTimestamp":1787920851,"startTime":"0","endTime":"0","summary":"百洋医药(301015.SZ)发布2026年半年度报告，实现营业收入35.6亿元，同比下降5.11%；归属于上市公司股东的净利润2.25亿元，同比增长37.72%。业绩增长主要系公司核心品牌运营业务稳健发展，自有主力品牌持续释放增长势能，同时公司主动压缩批发配送业务，聚焦核心主业提质增效。公司计划不派发现金红利，不送红股，不以公积金转增股本。注：公司Q2净利润1.01亿，Q1净利润1.24亿，据此计算，Q2净利润环比下降18%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800050432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662909361","title":"百洋医药最新公告：拟4000万元投资济坤医药拓展器官纤维化领域布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2662909361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662909361?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:39","pubTimestamp":1787920774,"startTime":"0","endTime":"0","summary":"百洋医药(301015.SZ)公告称，公司拟以现金方式向天津济坤医药科技有限公司投资4000万元，并与相关方签署《投资协议》。本次投资后公司持有济坤医药25.4399%股权，本次交易不会导致公司合并报表范围变更。本次投资构成关联交易，公司董事王廷伟担任济坤医药董事。济坤医药聚焦器官纤维化、炎症免疫及肿瘤领域创新药研发，拥有7条I类新药管线。本次投资旨在拓展公司在器官纤维化领域的布局，增强合作深度与广度。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800050436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","159938","BK1161","301015","BK0250","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658442932","title":"百洋医药（301015）披露归还临时补充流动资金的闲置募集资金公告，8月10日股价上涨1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658442932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658442932?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:28","pubTimestamp":1786372105,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘，百洋医药报收于24.23元，较前一交易日上涨1.51%，最新总市值为127.36亿元。该股当日开盘24.14元，最高24.57元，最低23.8元，成交额达2.39亿元，换手率为1.88%。公司于2026年8月10日披露《关于归还用于临时补充流动资金的闲置募集资金的公告》。截至2026年8月10日，公司已将实际用于临时补充流动资金的闲置募集资金54,992.29万元全部归还至募集资金专项账户，使用期限未超过12个月，并已通知保荐机构及保荐代表人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000034361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657262102","title":"百洋医药新提交“迪巧小粉条”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2657262102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657262102?lang=zh_cn&edition=full","pubTime":"2026-08-08 07:19","pubTimestamp":1786144757,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日美国安士制药有限公司新提交“迪巧小粉条”商标注册申请。商标申请详情如下：今年以来美国安士制药有限公司新申请注册商标4件，截止目前公司共持有注册商标437件，另有171件商标尚在注册申请中。结合公司2025年年报财务数据，2025年公司在研发方面投入了4216.52万元，同比增16.67%。通过天眼查大数据分析，青岛百洋医药股份有限公司共对外投资了36家企业，参与招投标项目332次；财产线索方面有商标信息570条，专利信息74条，著作权信息137条；此外企业还拥有行政许可64个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080800005871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652740679","title":"7月17日百洋医药跌6.32%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652740679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652740679?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:58","pubTimestamp":1784278711,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日百洋医药跌6.32%，收盘报22.23元，换手率3.07%，成交量16.13万手，成交额3.68亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。马泉林在任的基金产品包括:益民优势安享混合A，管理时间为2022年9月5日至今，期间收益率为40.86%；益民创新优势混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652406555","title":"百洋医药：提供ZAP-X放疗设备及配套技术支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2652406555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652406555?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:42","pubTimestamp":1784277726,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药07月17日在投资者关系平台上答复投资者关心的问题。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650920034","title":"百洋医药（301015）披露为子公司提供担保的进展公告，7月9日股价上涨2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650920034","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650920034?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:30","pubTimestamp":1783607434,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，百洋医药报收于22.08元，较前一交易日上涨2.94%，最新总市值为116.06亿元。该股当日开盘21.51元，最高22.6元，最低21.3元，成交额达2.58亿元，换手率为2.22%。公司于2026年7月9日发布《关于为子公司提供担保的进展公告》。上述担保事项均在公司2025年年度股东会审议通过的担保额度范围内，无需另行履行审议程序。本次担保后，公司及控股子公司对外担保总余额为37,852.16万元，占公司最近一期经审计净资产的15.37%，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900042593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789299210075,"stockEarnings":[{"period":"1week","weight":0.0205},{"period":"1month","weight":-0.0287},{"period":"3month","weight":0.1483},{"period":"6month","weight":0.0744},{"period":"1year","weight":-0.2344},{"period":"ytd","weight":0.0171}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"青岛百洋医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"15066人(较上一季度增加0.69%)","perCapita":"34883股","listingDate":"2021-06-30","address":"山东省青岛市市北区桐柏路88号1号楼","registeredCapital":"52562万元","survey":" 青岛百洋医药股份有限公司的主营业务是医学创新成果的产品开发、生产制造和商业化运营。公司的主要产品是品牌运营业务、批发配送业务。","listedPrice":7.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百洋医药,301015,百洋医药股票,百洋医药股票老虎,百洋医药股票老虎国际,百洋医药行情,百洋医药股票行情,百洋医药股价,百洋医药股市,百洋医药股票价格,百洋医药股票交易,百洋医药股票购买,百洋医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}